The Size of the MEA Antacid Market was valued at USD 1.34 billion in 2022 and is poised to reach USD 1.58 billion by the end of 2027, growing at a CAGR of 3.31% during the forecast period 2022 to 2027.
Antacids are usually over-the-counter (OTC) medications to relieve heartburn, indigestion, and other gastrointestinal diseases. Manufacturers in the MEA antacids market are focusing on formulating different drug solutions techniques to support a variety of products.
In 2050, this population is estimated to increase to 1.55 billion. Furthermore, the global population was aged 65 years or over has seen an increase from 6.23% in the early 1990s to 9.56% in 2019, with over 65% of the senior population suffering from acid reflux. In addition, geriatric patients are significant consumers of antacids as they are often suffering from indigestion, GERD, IBS, peptic ulcers, and others. These critical factors will boost the antacid market in the MEA region.
Patients suffer from several symptomatic disorders, such as erosive esophagitis, duodenal ulcers, Barrett esophagus, and esophageal cancer. Therefore, a combination of therapies is used for the treatment, requiring antacids to neutralize the harmful effects of gastric HCL. In addition, other factors such as poor lifestyle choices, inadequate sleep, stress, obesity, irregular dietary habits, and drug abuse have increased acidity level of the stomach and led to gastroesophageal reflux disease, whereby driving the MEA antacids market growth.
There has been a high incidence of Gastroesophageal Reflux Disease (GERD) globally over the several years. As per the recent article published by the International Foundation for Gastrointestinal Disorders in 2017, the prevalence of GERD was around 18.1% to 28.5% in North America, 9.5% to 26.6% in Europe, 3% to 8.5% in East Asia, 9.56% to 33.9% in the Middle East, 12.56% in Australia, and 23.5% in South America. Therefore, the launch of melt-in-mouth antacids has increased the market growth rate.
The side effects associated with antacids are major limiting factors in the market. Antacids common side effects include dose-dependent rebound hyperacidity, alkali syndrome, constipation, osteomalacia, hypophosphatemia, and reduced drug efficacy due to synergistic effects when combined with other acidic drugs. Moreover, other alternatives in the market will restrain the market.
This research report on the MEA Antacid Market has been segmented and sub-segmented into the following categories.
By Drug Class:
By Formulation Type:
By Distribution Channel:
Geographically, the Saudi Arabia antacid market and the UAE antacid market are estimated to grow significantly due to the growing geriatric population and well-developed healthcare facilities. Also, the increasing trend toward self-medication and purchase of products via E-commerce websites is on the rise.
In Saudi Arabia, a recent study conducted in the western region and Riyadh, performed using the GerdQ questionnaire of score ≥ 8 as a diagnostic criterion for GERD, recorded the prevalence range at 23.48% at 45.44%. The increase in these numbers and awareness about antacids will drive the market in the years to come.
Meanwhile, according to the aster clinic, factors such as lack of physical activity coupled with dense, fast food and spicy food consumption have resulted in the UAE region. It is having one of the highest rates of obesity in the world. GERD prevalence is recorded at nearly 3.12 million individuals across the seven Emirates nations.
KEY MARKET PLAYERS
Noteworthy companies l in the MEA Antacid Market profiled in this report are Sun Pharma, Digene (Abbott India), Pudin Hara (Dabur), Gelusil (Pfizer), GlaxoSmithKline plc, Abbott Laboratories, Pfizer, Inc.,
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: firstname.lastname@example.org